SYM-023 clinical trials
Also written Sym023 and Anti-TIM-3.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses SYM-023 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Anti-CD73 Monoclonal Antibody S095024 (1) · Anti-NKG2A Monoclonal Antibody Sym025 (1) · SYM-022 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test SYM-023.
- Apr 2027Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/2 · Servier Bio-Innovation LLC
Studies
Open first, then newest update. How each study uses SYM-023 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 1/2Servier Bio-Innovation LLCNCT06162572Written as S095018How we know
- Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor MalignanciesCompletedPhase 1Symphogen A/SNCT04641871Written as Sym023How we know
- Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasCompletedPhase 1Symphogen A/SNCT03489343Written as Sym023How we know
Given beside what is tested · 1 — SYM-023 is usual care or a partner of the new treatment
Codes
What other systems call SYM-023 · ClinicalTrials.gg INT015863
- UNII (FDA) 9GEU9XHE20SYM-023One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9GEU9XHE20 | SYM-023 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.